Dr. Clay Siegall is the president and Chief Executive officer of Seattle Genetics, a company he co-founded in 1998. Dr. Clay also serves as the chairman of the board of directors at Seattle Genetics. Under his leadership, the company has developed several lines of antibody-based cancer drugs. Before co-founding the company, Dr. Clay Siegall worked for Bristol-Myers Squibb, a pharmaceutical research institute for the period between 1991 and 1997. He had previously worked for the National Cancer from 1988 to 1991. He sits as a member of the board of directors of the biotechnology company, Alder Biopharmaceuticals.
Dr. Siegall went to the University of Maryland where he pursued a Bachelor of Science degree in Zoology. He furthered his studies by attending George Washington University from where he was awarded a Ph.D. in Genetics.Clay Siegall is also an author of over 70 publications and holds 15 patents.
Seattle Genetics focuses mainly on the human antibodies. The company has been studying, manipulating and packaging the antibodies into drugs since its inception in 1998. The action of antibodies arises from their ability to bind to something else. The antibodies can bind to cancer cells and delivers toxic substances that destroy the cells from inside. This strategy has the potential to put Seattle Genetics in the limelight of the big players in the pharmaceutical sector.
Today Seattle Genetics is worth $10 billion with a staff number of 900 employees; Seattle Genetics is the largest biotech company in Washington. The company envisions transitioning from biotech to a big pharmaceutical, and as such, it invests a lot in research and marketing and hiring more staff.
Seattle Genetics Drug Products
One of its flagship drugs Adcetris treats Hodgkin lymphoma (A type of cancer that affects the lymph system with the potential of spreading to other parts). If the current trials yield positive results, the company will start its sales. Adcetris is approved by the Food and Drug Administration and is currently undergoing research in comparison to other drugs. The company is also researching on Adcetris as a combination therapy with immuno-therapies.
Another product is a drug going by the number 33A treats acute myeloid leukemia. Myeloid leukemia is a blood cancer that has limited treatment options. 33A is still under studies that could see it introduced to the market. 22ME is another drug that targets cancer of the bladder and other urothelial cancers. The fourth drug is LIV1 that targets breast cancer.
Siegall envisions the company as an emerging global, oncology company which would offer various drugs for cancer. His ambition is to move the company focus beyond drug development to handling managing the complexity of marketing newer drugs internationally.